Biopharma | May 06, 2026
Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Lifts full-year outlook as obesity drug boom accelerates
But acquisition charges drag earnings into loss
The company posted revenue of €1,267 million, up 6% on a constant currency basis
The transaction marks a clear portfolio reshuffle for Indoco
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Subscribe To Our Newsletter & Stay Updated
